Bio-Techne (TECH) stock is back in focus after recent coverage of its latest results, where revenue missed expectations because of softer demand from emerging biotech customers and delayed cell therapy orders.

Bio-Techne’s recent earnings news has arrived against a backdrop where the share price is down 22.91% over the past month and 21.71% year to date. However, the 1 year total shareholder return is slightly positive at 0.51%, suggesting shorter term momentum has faded while longer term holders have seen only modest gains.

If this earnings reaction has you comparing opportunities across healthcare, it could be a useful moment to scan other companies using our screener focused on 30 healthcare AI stocks

With Bio-Techne’s stock down sharply in recent months and trading below analyst price targets and some intrinsic value estimates, the key question for you is whether this reset offers upside or if the market already reflects its future growth.

Most Popular Narrative: 38% Undervalued

Bio-Techne's most followed narrative pegs fair value at $75.25, well above the last close of $46.70, which puts a spotlight on the growth assumptions behind that gap.

The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100 to 200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (e.g., Leo Simple Western, Maurice) and digital platforms are driving high margin, high throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.

Want to see what kind of revenue path and margin profile need to line up to justify that higher fair value, and how future earnings are modeled to get there? The full narrative lays out the expected growth curve, the profitability step up, and the earnings multiple that ties those moving parts together.

Result: Fair Value of $75.25 (UNDERVALUED)

However, investors still need to weigh risks such as ongoing biotech funding pressure and potential tariff or regulatory shifts that could hit demand and compress margins.

Another View: Earnings Multiple Sends A Different Signal

While the narrative fair value of $75.25 suggests upside, the current P/E of 66.8x is far above the estimated fair ratio of 21.2x and above both peer average at 50.2x and the global Life Sciences average at 35.1x. That gap points to valuation risk, so which signal do you trust more right now?

Next Steps

With mixed signals across valuation and fundamentals, the question is what matters most to you right now. Move quickly to review the balance of 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your goals even better, so consider putting a few more ideas on your radar today.

• Target resilient income by reviewing companies with strong yields and staying power using our 10 dividend fortresses.
• Hunt for quality at a reasonable price by scanning 51 high quality undervalued stocks that pair robust fundamentals with attractive valuations.
• Spot lesser-known opportunities before the crowd by running the screener containing 21 high quality undiscovered gems and seeing which companies stand out on the numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.